New perspectives for the treatment of hepatitis C.
-la Hepatitis C is an infectious disease affecting the liver, and that after years of evolution is frequently associated with severe chronic liver failure
Zaragoza, April of 2013.- El Instituto Aragonés de Ciencias of the Salud in collaboration with the pharmacological Therapeutics of the University Hospital of Navarra innovation classroom called the March 18 in a forum of debate experts in this liver disease, which affects between 1.5 and 2.5% of the Spanish population. The meeting, entitled Hepatitis c: present and future ” took place at the Hospital ClÃnico Universitario Lozano Blesa ”
explained the experts during the discussion forum, the arrival in the therapeutic armamentarium against this disease of the protease inhibitors can change the prognosis of the disease. At the moment, two of these new drugs–Telaprevir and Boceprevir, together with those already used so far, interferon and Ribavirin allow increase the rate of healing of the sick by hepatitis C from 50% to 75% on average. This raises a new landscape and is a hopeful change in the treatment of hepatitis C. Thus, the Forum discussed this new perspective from different points of view: the patient, administration and medical specialists.
The two new drugs were authorized last year by the European Commission and by the Spanish Agency of medicines and health products through an accelerated centralized procedure given its promising results, and are managing in patients from a few months ago. Aragon has created a protocol for action, according to the criteria of the Spanish Agency of medicines and health products. To date already have been evaluated and authorized more than 100 treatments for patients with hepatitis c virus
